Levels of α-Gal IgG3, IgG4 and, particularly, IgM are associated with protection against clinical malaria, while total IgG levels correlate with malaria risk, supporting further investigations of α-Gal as a promising antigen target for future malaria vaccines. This evidence concerns the gene CD40LG and malaria.